Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia

Diagnostic Microbiology and Infectious Disease

Volumn 68, Issue 2, 2010, Pages 140-151

  Freire, Antonio T ^a   Melnyk, Vasyl ^b   Kim, Min Ja ^c   Datsenko, Oleksiy ^d   Dzyublik, Oleksandr ^e   Glumcher, Felix ^f   Chuang, Yin Ching ^g   Maroko, Robert T ^h   Dukart, Gary ^h   Cooper, C Angel ^h   Korth Bradley, Joan M ^h   Dartois, Nathalie ^h   Gandjini, Hassan ^h  

^a Santa Efigênia Belo Horizonte MG ^*  (Brazil)

^b Kyiv City Tuberculosis and Pulmonology Hospital   (Ukraine)

^c Korea University College of Medicine   (South Korea)

^d KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^e Central Military Clinical Hospital   (Ukraine)

^f BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^g CHI MEI MEDICAL CENTER   (Taiwan)

^h PFIZER INC   (United States)

Author keywords

Antimicrobial; Glycylcycline; Nosocomial; Pneumonia; Ventilator non ventilator associated pneumonia

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; PLACEBO; TIGECYCLINE; VANCOMYCIN;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BLEEDING TENDENCY; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DECUBITUS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HOSPITAL INFECTION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPROTEINEMIA; HYPOTENSION; INFECTION; KIDNEY DYSFUNCTION; LEUKOCYTOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; MULTICENTER STUDY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PERITONITIS; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SHOCK; SIDE EFFECT; SKIN ULCER; SOMNOLENCE; STEADY STATE; THROMBOCYTHEMIA; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CILASTATIN; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HOSPITAL MORTALITY; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMONIA; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

EID: 77956576770     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.05.012     Document Type: Article

References (35)

1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care. Med. 2005, 171:388-416. American Thoracic Society.
2. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 2005, 41(Suppl. 5):S354-367. Tigecycline 301 Study Group, Tigecycline 306 Study GroupTigecycline 306 Study Group.
3. Burkhardt O., Rauch K., Kaever V., Hadem J., Kielstein J.T., Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int. J. Antimicrob. Agents 2009, 34:101-102.
4. Celis R., Torres A., et al. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988, 93:318-324.
5. Connelly S.M., Trinh J.V., Johnson M.D., Dodds-Ashley E.S., Stout J., Engemann J.J., Friedman N.D., Kaye D., Kaye K.S. Mortality and time to extubation in severe hospital-acquired pneumonia. Am. J. Infect. Control 2009, 37:143-149.
6. Conte J.E., Golden J.A., Kelly M.G., Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 2005, 25:523-529.
7. Craven D.E., Steger K.A., Barber T.W. Preventing nosocomial pneumonia: state of the art and perspectives from the 1990's. Am. J. Med. 1991, 91:44s-53s.
8. Curcio D., Fernández F., Vergara J., Vazquez W., Luna C.M. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J. Chemother. 2009, 21:58-62.
9. Edelstein P.H., Weiss W.J., Edelstein M.A. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 2003, 47:533-540.
10. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 2005, 41(Suppl. 5):S341-353. Tigecycline 300 cSSSI Study Group, Tigecycline 305 cSSSI Study GroupTigecycline 305 cSSSI Study Group.
11. Entenza J.M., Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int. J. Antimicrob. Agents 2009, 34:8.e1-8.e9.
12. Fink M.P., Snydman D.R., Niederman M.S., Leeper K.V., Johnson R.H., Heard S.O., Wunderink R.G., Caldwell J.W., Schentag J.J., Siami G.A., Zameck R.L., Haverstock D.C., Reinhart H.H., Echols R.M. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 1994, 38:547-557. and the Severe Pneumonia Study Group.
13. Fritsche T.R., Jones R.N. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int. J. Antimicrob. Agents 2004, 24:567-571.
14. Giamarellou H., Mandragos K., Bechrakis P., Pigas K., Bilalis D., Sfikakis P. Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. J. Antimicrob. Chemother. 1990, 26:117-127.
15. Hartenauer U., Weilemann L.S., Bodmann K.F., Ritzerfeld W.W., Asmus S., Koch E.M. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J. Hosp. Infect. 1990, 15:61-64.
16. Heyland D.K., Cook D.J., Griffith L., Keenan S.P., Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am. J. Respir. Crit. Care Med. 1999, 159:1249-1256.
17. Joshi M., Metzler M., McCarthy M., Olvey S., Kassira W., Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir. Med. 2006, 100:1554-1565.
18. Knaus W.A., Harrell F.E., Lynn J., Goldman L., Phillips R.S., Connors A.F., Dawson N.V., Fulkerson W.J., Califf R.M., Desbiens N., Layde P., Oye R.K., Bellamy P.E., Hakim R.B., Wagner D.P. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann. Intern. Med. 1995, 122:191-203.
19. Koomanachai P., Crandon J.L., Banevicius M.A., Peng L., Nicolau D.P. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob. Agents Chemother. 2009, 53:5060-5063.
20. Koomanachai P., Kim A., Nicolau D.P. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J. Antimicrob. Chemother. 2009, 63:982-987.
21. Kuti J.L., Dowzicky M., Nicolau D.P. A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. J. Chemother. 2008, 20:69-76.
22. Maclayton D.O., Hall R.G. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann. Pharmacother. 2007, 41:235-244.
23. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., Ellis-Grosse E.J., Ambrose P.G. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother. 2007, 51:1939-1945.
24. Mikels S.M., Brown A.S. In vivo activities of GAR-936, gentamicin, piperacillin, alone and in combination in a murine model of Pseudomonas aeruginosa 1999.
25. Muralidharan G., Micalizzi M., Speth J., Raible D., Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 2005, 49:220-229.
26. Passarell J.A., Meagher A.K., Liolios K., Cirincione B.B., Van Wart S.A., Babinchak T., Ellis-Grosse E.J., Ambrose P.G. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother. 2008, 52:204-210.
27. Postier R.G., Green S.L., Klein S.R., Ellis-Grosse E.J., Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 2004, 26:704-714. Tigecycline 200 Study Group.
28. Poulakou G., Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin. Investig. Drugs 2007, 16:137-155.
29. Rello J., Paiva J.A., Baraibar J., Barcenilla F., Bodi M., Castander D., Correa H., Diaz E., Garnacho J., Llorio M., Rios M., Rodriguez A., Solé-Violán J. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001, 120:955-970.
30. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 2006, 58:1221-1229.
31. Sader H.S., Jones R.N., Dowzicky M.J., Fritsche T.R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 2005, 52:203-208.
32. Tanaseanu C., Bergallo C., Teglia O., Jasovich A., Oliva M.E., Dukart G., Dartois N., Cooper C.A., Gandjini H., Mallick R. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2008, 61:329-338. 308 Study Group, 313 Study Group313 Study Group.
33. Van Wart S.A., Owen J.S., Ludwig E.A., Meagher A.K., Korth-Bradley J.M., Cirincione B.B. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob. Agents Chemother. 2006, 50:3701-3707.
34. Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2005, 41(Suppl. 4):S269-S272.
35. West M., Boulanger B.R., Fogarty C., Tennenberg A., Wiesinger B., Oross M., Wu S.C., Fowler C., Morgan N., Kahn J.B. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin. Ther. 2003, 25:485-506.